Answers are grounded in this paper and cite their sources.
Even though naratriptan and sumatriptan are both 5-HT1B/5-HT1D receptor agonists, the biological and pharmacokinetic profile of naratriptan differs significantly from that of sumatriptan. With a plasma half-life of 6 h, very high oral bioavailability of 63-74% and higher lipophilicity than sumatriptan, naratriptan exhibits a distinct clinical therapeutic profile. The similar tolerability to placebo, prolonged efficacy for 24 h or more and very low headache recurrence rate make naratriptan an attractive option in the treatment of acute migraine.
No takes yet. Share an insight, caveat, or question.
Ninan T. Mathew (1999) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: